Donor blood availability: from collection to the patient
A blood collection slot, a completed donation and a compatible component at the bedside represent different stages of access. This guide connects those stages with emergency-care and oxygen-delivery research.
Availability is a sequence
The existing BHOC capacity analysis separates the opportunity to collect blood from the donations that successfully enter the supply pathway. Collection capacity alone cannot describe the blood available for a particular patient at a particular time.
The next questions concern processing, inventory, compatibility, distribution and clinical access. A supply measure should name its stage and denominator before it is compared across systems.
The emergency window
The prehospital setting makes the access problem concrete. An EMS team must connect hemorrhage control, transport, clinical assessment and access to blood products before definitive hospital care. A national collection total does not answer whether the needed component can reach that patient in time.
Our EMS page brings together dated program and blood-supply sources. Its operational figures describe their own reporting periods and populations; they should not be treated as estimates of BHOC impact.
Global access and local delivery
The WHO blood-access analysis and the BHOC emergency-care materials address related but distinct questions: whether a health system can maintain a safe supply, and whether an individual service can deliver it when and where it is needed.
Maternal hemorrhage, remote care and severe anemia expose different parts of this sequence. They belong in the same access discussion, while their clinical protocols and evidence remain separate.
A complementary oxygen-delivery research question
BHOC development asks whether an additional oxygen-delivery capability could help during an interval in which donor blood is delayed or unavailable. This is a research objective alongside hemorrhage control, transfusion systems and definitive care.
A practical evaluation would measure the complete pathway: handling, time to administration, dose and volume, physiological response and the resources needed to operate the service. A proposed shelf-life or logistics advantage requires its own product-specific verification.